That was my understanding as well. However, NP

That was my understanding as well.

However, NP should have known this last week that it would be delayed when he made a statement along the lines of I spoke with Kush Dhody at Amarex that said it was still on track for January submission.....missing by a few days or even a week is understandable due to the work required, but adding 4 weeks to the timeline due to the amount of work doesn't sound like it was on track for January submission last week. NP knew at this time that the FDA requested data from the CD03 trial, so the only 2 reasons I can think of is that Kush Khody didn't understand or severely underestimated the amount of data the FDA requested (he seems like a smart guy as he is VP of clinical operations at Amarex and has several 3 and 4 letter certifications in his signature block) or NP didn't want to accept a delay until it was officially delayed and as a result also failed to set shareholder expectations.

It is what it is and everything outside of this delay was positive on the call, so I don't want to focus on the only negative that will (hopefully) be resolved in a few weeks.

Please do your own due diligence. All my posts and comments are not to be considered investment advice.